Clinical Trial Update: Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating adding Sonrotoclax to Zanubrutinib for patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Leukemia

Drugs mentioned

• Sonrotoclax
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 3 | Status: NOT_YET_RECRUITING